New drug combo tested for Tough-to-Treat leukemia
NCT ID NCT02787369
Summary
This early-stage study is testing whether adding an experimental drug called ACY-1215 to existing leukemia medications (ibrutinib or idelalisib) is safe and tolerable for adults with chronic lymphocytic leukemia (CLL) that has returned after prior treatment. The main goal is to find the highest dose of ACY-1215 that can be given safely in combination. Researchers hope this combination might improve treatment responses for patients who have relapsed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CHRONIC LYMPHOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.